Alkaline Phosphatase + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sepsis
Conditions
Sepsis, Multiple Organ Dysfunction Syndrome
Trial Timeline
Sep 1, 2004 → Mar 1, 2006
NCT ID
NCT00430859About Alkaline Phosphatase + Placebo
Alkaline Phosphatase + Placebo is a phase 2 stage product being developed by AM-Pharma for Sepsis. The current trial status is completed. This product is registered under clinical trial identifier NCT00430859. Target conditions include Sepsis, Multiple Organ Dysfunction Syndrome.
What happened to similar drugs?
9 of 19 similar drugs in Sepsis were approved
Approved (9) Terminated (1) Active (9)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00430859 | Phase 2 | Completed |
Competing Products
20 competing products in Sepsis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Drotrecogin alfa (activated) | Eli Lilly | Phase 2 | 35 |
| Meropenem | Pfizer | Approved | 43 |
| Imipenem | Merck | Approved | 39 |
| Cefiderocol | Shionogi | Phase 1 | 29 |
| eritoran tetrasodium + Placebo | Eisai | Phase 3 | 40 |
| E5564 | Eisai | Phase 2 | 35 |
| Drotrecogin Alfa (Activated) + placebo | Eli Lilly | Phase 3 | 40 |
| Drotrecogin alfa (activated) + Placebo | Eli Lilly | Phase 3 | 40 |
| Drotrecogin Alfa (activated) | Eli Lilly | Approved | 43 |
| Drotrecogin alfa (activated) + Placebo | Eli Lilly | Phase 3 | 40 |
| Drotrecogin alfa (activated) + Placebo | Eli Lilly | Phase 3 | 40 |
| sPLA2 Inhibitor | Eli Lilly | Phase 1/2 | 32 |
| Drotrecogin alfa (activated) | Eli Lilly | Approved | 43 |
| Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparin | Eli Lilly | Approved | 43 |
| drotrecogin alfa (activated) | Eli Lilly | Approved | 43 |
| drotrecogin alfa (activated) | Eli Lilly | Approved | 43 |
| AZD9773 (CytoFab) | AstraZeneca | Phase 2 | 35 |
| AZD9773 + Placebo | AstraZeneca | Phase 2 | 35 |
| AZD9773 + Placebo | AstraZeneca | Phase 2 | 35 |
| AZD4144 + Placebo | AstraZeneca | Phase 2 | 42 |